Deutsche Bank AG Invests $51.15 Million in Insulet Corporation $PODD

Deutsche Bank AG purchased a new position in Insulet Corporation (NASDAQ:PODD) during the second quarter, Holdings Channel reports. The fund purchased 335,980 shares of the medical instruments supplier’s stock, valued at approximately $51,153,000.

Other institutional investors also recently added to or reduced their stakes in the company. Mitsubishi UFJ Trust & Banking Corp boosted its stake in Insulet by 26.5% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock valued at $12,484,000 after acquiring an additional 9,206 shares during the last quarter. OP Asset Management Ltd purchased a new stake in shares of Insulet during the 1st quarter worth approximately $1,513,000. Strs Ohio increased its stake in shares of Insulet by 36.0% during the 4th quarter. Strs Ohio now owns 22,680 shares of the medical instruments supplier’s stock worth $6,447,000 after purchasing an additional 6,003 shares during the last quarter. Swedbank AB raised its holdings in shares of Insulet by 11.0% in the 4th quarter. Swedbank AB now owns 85,988 shares of the medical instruments supplier’s stock worth $24,441,000 after purchasing an additional 8,500 shares during the period. Finally, SEB Asset Management AB bought a new stake in shares of Insulet in the 1st quarter worth approximately $24,700,000.

Insider Activity

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Insulet Price Performance

Shares of NASDAQ PODD opened at $146.87 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The stock has a market cap of $10.19 billion, a PE ratio of 27.45, a price-to-earnings-growth ratio of 1.19 and a beta of 1.10. The stock has a fifty day moving average of $154.70 and a 200-day moving average of $185.07.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s quarterly revenue was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PODD. Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Deutsche Bank Aktiengesellschaft started coverage on Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price target on the stock. Wall Street Zen downgraded Insulet from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 9th. Citigroup increased their price target on Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $205.00 price objective on shares of Insulet in a report on Wednesday, May 27th. Fourteen analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Insulet presently has a consensus rating of “Hold” and an average target price of $195.40.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Insulet and certain executives. The complaints allege that the company made materially false or misleading statements about manufacturing controls, product quality, and the safety and reliability of Omnipod devices. The allegations have not been proven in court. Pomerantz class action announcement
• Negative Sentiment: The investor notices link the case to two Omnipod medical-device corrections and claim that related disclosures contributed to a substantial decline in Insulet’s stock. One notice cited a move from $236.07 to $146.01 across the alleged corrective disclosures, or losses exceeding $90 per share for some investors. SueWallSt investor notice
• Negative Sentiment: The legal overhang intensified as several firms—including Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, Bernstein Liebhard, Glancy Prongay, Robbins LLP, Levi & Korsinsky, and Portnoy—urged affected shareholders to seek lead-plaintiff status or evaluate potential recovery. The deadline to move for lead-plaintiff appointment is August 31, 2026. Robbins Geller deadline announcement

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.